Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380

News   Feb 22, 2014

 
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380
 
 
 
 

RELATED ARTICLES

Shedding Light on How Tumors Become Resistant to Immunotherapy

News

Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.

READ MORE

Ingestible Drug-Delivery Materials May Improve Patient Treatment Compliance

News

Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.

READ MORE

Nanoparticle Delivery of Curcumin Induces Tumor Cell Death

News

Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE